Terms: = Lung cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
293 results:
1. treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
2. cdk4/6 inhibitors in lung cancer: current practice and future directions.
Lv S; Yang J; Lin J; Huang X; Zhao H; Zhao C; Yang L
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38355149
[TBL] [Abstract] [Full Text] [Related]
3. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
4. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract] [Full Text] [Related]
5. Interstitial lung disease and cdk4/6 inhibitors in the treatment of breast cancer.
Schlam I; Giordano A; Tolaney SM
Expert Opin Drug Saf; 2023; 22(12):1149-1156. PubMed ID: 37994878
[TBL] [Abstract] [Full Text] [Related]
6. Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway.
Hou M; Li H; He T; Hui S; Dai W; Hou X; Zhao J; Zhao J; Wen J; Kan W; Xiao X; Zhan X; Bai Z
J Pharm Pharmacol; 2024 May; 76(5):499-513. PubMed ID: 37971302
[TBL] [Abstract] [Full Text] [Related]
7. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
8. Notopterol Suppresses IL-17-Induced Proliferation and Invasion of A549 lung Adenocarcinoma Cells via Modulation of STAT3, NF-κB, and AP-1 Activation.
Inthanon S; Dejkriengkraikul P; Yodkeeree S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894738
[TBL] [Abstract] [Full Text] [Related]
9. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
Volta F; La Monica S; Leonetti A; Gnetti L; Bonelli M; Cavazzoni A; Fumarola C; Galetti M; Eltayeb K; Minari R; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2023 Nov; 18(6):953-964. PubMed ID: 37855989
[TBL] [Abstract] [Full Text] [Related]
10. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J; Sakai H; Tsurutani J; Tanabe Y; Masuda N; Iwasa T; Takahashi M; Futamura M; Matsumoto K; Aogi K; Iwata H; Hosonaga M; Mukohara T; Yoshimura K; Imamura CK; Miura S; Yamochi T; Kawabata H; Yasojima H; Tomioka N; Yoshimura K; Takano T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709297
[TBL] [Abstract] [Full Text] [Related]
12. Utility of psychotherapy assessed with Kessler scale in a population of cancer patients undergoing systemic oncological treatment: a mono-institutional experience.
Vitale P; Bocchino I; De Falco V; Auletta G; Di Giovanni I; Bocchetti M; Auriemma A; Conchiglia R; Addeo R
Chin Clin Oncol; 2023 Aug; 12(4):35. PubMed ID: 37699600
[TBL] [Abstract] [Full Text] [Related]
13. Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from cdk4/6 Inhibitor.
Hunt A; Haque W; Pino R; Farach A; Butler EB; Teh BS
Anticancer Res; 2023 Aug; 43(8):3539-3542. PubMed ID: 37500128
[TBL] [Abstract] [Full Text] [Related]
14. FSIP1 enhances the therapeutic sensitivity to cdk4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G; Sun L; Gu X; Ai L; Yang J; Zhang Z; Hou P; Wang Y; Ou X; Jiang X; Qiao X; Ma Q; Niu N; Xue J; Zhang H; Yang Y; Liu C
Sci China Life Sci; 2023 Dec; 66(12):2805-2817. PubMed ID: 37460715
[TBL] [Abstract] [Full Text] [Related]
15. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
16. Dexamethasone induces cancer mitigation and irreversible senescence in lung cancer cells via damaging cortical actin and sustained hyperphosphorylation of pRb.
Srivastava S; Siddiqui S; Singh S; Chowdhury S; Upadhyay V; Sethi A; Kumar Trivedi A
Steroids; 2023 Oct; 198():109269. PubMed ID: 37394085
[TBL] [Abstract] [Full Text] [Related]
17. Say 'No' to cancer and 'Yes' to Cranberry: The Role of Cranberry Extract in Inhibition of Growth of lung Adenocarcinoma Cells.
Zhao L; Kaser E; Lequio M; D'Mello K; Xiao H; Luechtefeld HD; Mayberry TG; Bai Q; Wakefield MR; Fang Y
Anticancer Res; 2023 Jul; 43(7):2933-2939. PubMed ID: 37351982
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of Mitochondrial Antioxidant Defense and cdk4/6 in Mesothelioma.
Kratzke M; Scaria G; Porter S; Kren B; Klein MA
Molecules; 2023 May; 28(11):. PubMed ID: 37298855
[TBL] [Abstract] [Full Text] [Related]
19. Adolescent, caregiver and provider perspectives on tuberculosis treatment adherence: a qualitative study from Lima, Peru.
Chiang SS; Senador L; Altamirano E; Wong M; Beckhorn CB; Roche S; Coit J; Oliva Rapoport VE; Lecca L; Galea JT
BMJ Open; 2023 May; 13(5):e069938. PubMed ID: 37202135
[TBL] [Abstract] [Full Text] [Related]
20. Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report.
Yoneto T; Hasumi K; Takahashi N; Seki N; Takeda Y; Yoshimoto T
J Med Case Rep; 2023 May; 17(1):190. PubMed ID: 37158934
[TBL] [Abstract] [Full Text] [Related]
[Next]
